Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2014-001063-12-GB
EUCTR2014-001063-12-GBActive, not recruitingPhase 1

A phase III, multi-center, randomized, double blind, active and placebo control, single dose trial to demonstrate the efficacy and safety of DWP-450 in adult subjects for treatment of moderate-to-severe glabellar lines - EV003

Evolus Inc.0 sites497 target enrollmentStarted: March 24, 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
497
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •-Subject is an adult, of at least 18 years of age
  • •-Subject understands and signs the informed consent and can comply with study instructions
  • •-Subject has moderate to severe glabellar lines at maximum frown as assessed by the investigator using the GLS (GLS=2 or 3)
  • •-Subject is willing and able to complete the entire course of the study
  • •-Subject finds their glabellar lines have an important psychological impact (on mood, anxiety and/or depressive symptoms)
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 435
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 62

Exclusion Criteria

  • •A subject must not meet the following key exclusion criteria in order to be eligible for enrollment in the study:
  • •-Previous treatment with botulinum toxin of any serotype in the forehead area within the last 6 months
  • •-Previous treatment with any facial aesthetic procedure (e.g., injection with fillers, chemical peeling, photo rejuvenation) in the glabellar area within the last 12 months
  • •-Previous insertion of permanent material in the glabellar area
  • •-Planned treatment with botulinum toxin of any serotype in any other body region during the study period
  • •-Any surgery in the glabellar area including surgical removal of the corrugator, procerus, or depressor supercilii muscles or a combination of these, or scars in the glabellar area and the surrounding areas (including eye brow)
  • •-Energy based or cryo-therapy based treatment of facial muscles superior to the lateral canthus
  • •-Any other planned facial aesthetic procedure during the trial period, superior to the level of the lateral canthus (can continue with their usual skin care routine)
  • •-Subjects not reasonably expected to respond to 20 units of botulinum toxin (e.g., inability to substantially lessen glabellar frown lines even by physically spreading them apart)
  • •-Marked facial asymmetry
  • •-Ptosis of eyelid and/or eyebrow, or history of eyelid and/or eyebrow ptosis
  • •-History of facial nerve palsy
  • •-Excessive dermatochalasis, deep dermal scarring, thick sebaceous skin
  • •-Any active infection or history of herpes simplex or herpes zoster in the area of the injection sites
  • •-Medical condition that may affect neuromuscular function (e.g., myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis)
  • •-History of dysphagia or aspiration
  • •-Subjects with prolonged bleeding times. If on a drug or supplement that prolongs bleeding times (eg non-steroidal, anti-inflammatory, anticoagulant, fish oil), wait 10 days or until bleeding times return to normal before injecting
  • •-Evidence of recent alcohol or drug abuse
  • •-Medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study
  • •-Breast feeding, pregnant or sexually active female subjects who are of childbearing potential and who are not willing to use an acceptable form of contraception
  • •-Individuals who may be unduly influenced or fear a retaliatory response by hierarchy at the study center during the study
  • •-Known allergy or hypersensitivity to botulinum toxin preparation
  • •-Participation in another interventional clinical study within the last 30 days

Investigators

Similar Trials

Active, not recruiting
Phase 1
A clinical trial demonstrating the safety and efficacy of treatment of lines between the eye brows with the test drug DWP-450 in adults by comparison with Botox and Placebo.
EUCTR2014-001063-12-SEEvolus Inc.497
Active, not recruiting
Phase 1
A clinical trial demonstrating the safety and efficacy of treatment of lines between the eye brows with the test drug DWP-450 in adults by comparison with Botox and Placebo.moderate-to-severe glabellar linesMedDRA version: 17.1Level: LLTClassification code 10052609Term: Glabellar frown linesSystem Organ Class: 100000004858
EUCTR2014-001063-12-DEEvolus Inc.497
Completed
Phase 3
ovel Corona Virus-2019-nCov vaccine by intradermal route inhealthy subjects.
CTRI/2021/01/030416Cadila Healthcare Ltd28,216
Active, not recruiting
Phase 1
Placebo-controlled study of the safety and efficacy of osilodrostat in patients with Cushing's DiseaseCushing's diseaseMedDRA version: 20.0Level: LLTClassification code 10011651Term: Cushing's diseaseSystem Organ Class: 100000004860
EUCTR2014-004092-23-PTovartis Pharma Services AG74
Active, not recruiting
Not Applicable
A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide administered monthly for 24 weeks in subjects with symptomatic endometriosis.MedDRA version: 7Level: LLTClassification code 10014778Endometriosis
EUCTR2004-001720-21-GBTakeda Europe R&D Centre Ltd200